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ANTIHYPERTENSIVE 
DRUGS
BACKGROUND
Hypertensive disorders of pregnancy (HDP) are major causes of severe 
morbidity, long-term disability, and death of mothers and babies. Glob-
ally, about 10 percent of women experience increased blood pressure 
(BP) during pregnancy, and 2-8 percent of pregnancies are complicated 
by pre-eclampsia. Among them, 10 percent develop severe pre-eclamp-
sia and eclampsia. About 10-20 percent of all maternal deaths are from 
eclampsia, the second leading direct cause of maternal mortality. 
Expanding proven, high impact practices is critical to accelerating a 
global reduction in maternal and perinatal morbidity and mortality. The 
need is especially acute in low- and middle-income countries (LMICs) 
of sub-Saharan Africa and South Asia, where 65-85 percent of the pop-
ulations are rural and have limited access to life-saving care. Sixteen 
percent of all maternal deaths in LMICs are from HDP, with women in 
LMICs being 300 times more likely to die from eclampsia than those in 
developed countries. 
The etiology of pre-eclampsia and eclampsia (PE/E) is unclear, but it is 
a multi-system disorder impacting cardiovascular and neurological func-
tions. What is clear is PE/E-related deaths are preventable with early de-
tection during antenatal care through BP monitoring and management 
with antihypertensive drugs and magnesium sulphate (MgSO4). 
MgSO4 is used for preventing and treating convulsions from severe 
pre-eclampsia and eclampsia, respectively, and is one of 13 essential 
commodities identified by the UN Commission on Life-saving Commod-
ities for Women and Children. However, MgSO4 alone does not address 
the complex signs and symptoms that women with pre-eclampsia expe-
rience. Although safe, low-cost, and effective, MgSO4 is an anticonvul-
sant but it does not treat hypertension. If it is not stabilized, there is an 
increased risk of major adverse cardiovascular events, such as stroke 
and death. It is critical to use antihypertensive drugs to lower high BP.
MANAGING HYPERTENSION DURING PREGNANCY
Most women with pre-eclampsia have hypertension, meaning the syst-
solic BP is above 140mmHg and the diastolic BP is above 90mmHg. 
Hypertension can be mild (≥140/90 - <150/100mmHg), moderate 
(≥150/100 - <160/110mmHg), or severe (≥160/110mmHg). Moderate 
and severe hypertension require treatment with antihypertensive drugs. 
Highlights
1. Pre-eclampsia is a condition in
pregnant women marked by an
increase in blood pressure and
protein in urine after 20 weeks
gestation.
2. Eclampsia is a life-threatening
condition characterized by convul-
sions in women with PE.
3. PE/E and other hypertensive dis-
orders in pregnancy increase the
risk of pre-term births.
4. Providing high quality and regular
(ideally eight contacts) antenatal
care improves the prevention and
early detection of pre-eclampsia
and can prevent its progression to
eclampsia.
5. Prescribing low-dose aspirin and
calcium to at-risk women can pre-
vent pre-eclampsia and eclampsia.
6. Pre-eclampsia and eclampsia can
be managed by administering an-
tihypertensive drugs and magne-
sium sulphate (MgSO4).
7. MgSO4 is the safest and most ef-
fective treatment for severe PE/E,
and is one of 13 UN Life-Saving
Commodities for Women and
Children.
8. Improved prevention, increased
detection, and effective treatment
of PE/E can prevent unnecessary-
maternal and newborn deaths.
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A Cochrane systematic review found that antihypertensive drugs 
low-er the risk of developing severe hypertension. The WHO 
recommends that every health facility have adequate oral and 
intravenous antihy-pertensive drugs in the antenatal, labor, and 
maternity units. If the sys-tolic blood pressure is 160 mmHg or more 
or the diastolic blood pres-sure is 110 mmHg or more, prescribe 
antihypertensive drugs. There are four antihypertensive drugs – 
labetalol, hydralazine, methyldopa, and nifedipine – that are safe to 
use during pregnancy.
Despite being safe, low-cost, effective, and commonly 
available, LMICs, countries and programs do not procure antihy-
pertensive drugs in quantities large enough to meet the demand 
for managing high BP in pregnancy. However in 2016, members 
of Maternal Health Caucus of the Repro-ductive Health Supplies 
Coalition agreed anti-hypertensives should be part of the 
essential medicines list for maternal health.
Challenges in ensuring that women have access to antihypertensive 
drugs to control their BP during pregnancy include the following: 
• National task shifting policies do not allow management of HDP
at the primary healthcare (PHC) facility level, even though they are
mandated to administer a loading dose of MgSO4 prior to referral.
• Stock out of antihypertensive drugs at PHC facilities
• Additional cost of training PHC health workers to monitor BP and
prescribe antihypertensive drugs correctly.
• Lack of support for task shifting from professional bodies.
The problem lies with national policies that enable or prohibit task 
shifting to providers at primary healthcare facilities. In many countries, 
the administration of a loading dose of MgSO4 to women with PE/E 
has been shifted to lower cadre providers (e.g., the community health 
extension workers), but the control of hypertension during pregnancy, 
including PE/E, is not  included in national task shifting policies. 
CONCLUSION
HDP, including PE/E, is a major cause of maternal and fetal mortali-
ty and morbidity globally. To prevent these deaths, early detection of 
the disease during pregnancy and appropriate use of antihyperten-
sive drugs (and MgSO4, when indicated) are recommended for women 
with severe hypertension during and after pregnancy. It is, therefore, 
crucial that the four antihypertensive drugs that are safe to use in 
pregnancy - labetalol, hydralazine, methyldopa, and nifedipine - are 
included on the essential MNH drug list and distributed to every 
health facility in every country.
The Ending Eclampsia project seeks to expand 
access to proven,underutilized interventions and 
commodities for the prevention, early detection, 
and treatment of pre-eclampsia and eclampsia and 
strengthen global partnerships. 
